Skip to content

Psilocybin research published in 2020

Page 3 of 7: studies 41 to 60 of 123, newest first. Back to the psilocybin overview

Studies

Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders

International Journal of Molecular Sciences September 7, 2020 Matas Vitkauskas, Ajay S. Mathuru 4 citations

Depression impacts the lives and daily activities of millions globally. Research into the neurobiology of lateral habenula circuitry and the use of psychedelics for treating depressive states has emerged in the last decade as new directions to devise interventional strategies and therapies. Several clinical trials using deep brain stimulation of the habenula, or using ketamine, and psychedelics...

Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials

Biomedicines September 5, 2020 Ana Sofia Vargas, Ângelo Luís, Mário Barroso et al. 121 citations

Psilocybin is a naturally occurring tryptamine known for its psychedelic properties. Recent research indicates that psilocybin may constitute a valid approach to treat depression and anxiety associated to life-threatening diseases. The aim of this work was to perform a systematic review with meta-analysis of clinical trials to assess the therapeutic effects and safety of psilocybin on those...

DOI: 10.3390/biomedicines8090331 (opens in new tab) Psilocybin Anxiety Context archaeology Beck depression inventory +6

Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.

Neuroimage September 1, 2020 Frederick S. Barrett, Samuel R Krimmel, Roland R. Griffiths et al. 191 citations

Psychedelic drugs, including the serotonin 2a (5-HT2A) receptor partial agonist psilocybin, are receiving renewed attention for their possible efficacy in treating a variety of neuropsychiatric disorders. Psilocybin induces widespread dysregulation of cortical activity, but circuit-level mechanisms underlying this effect are unclear. The claustrum is a subcortical nucleus that highly expresses...

DOI: 10.1016/j.neuroimage.2020.116980 (opens in new tab) Full text (opens in new tab) Psychedelics Serotonin 2a receptor Claustrum connectivity Psychedelic effects +1

The Psilocin (4-hydroxy-N,N-dimethyltryptamine) and Bufotenine (5-hydroxy-N,N-dimethyltryptamine) Case: Ensuring the Correct Isomer has Been Identified.

Journal of Forensic Sciences September 1, 2020 Tehila Mishraki-Berkowitz, Esti Kochelski, Pierce V. Kavanagh et al. 12 citations

Psilocin (4-hydroxy-N,N-dimethyltryptamine, 4-HO-DMT) and bufotenine (5-hydroxy-N,N-dimethyltryptamine, 5-HO-DMT), which are both naturally occurring compounds, are classified as controlled substances in numerous countries due to their pharmacological activities and recreational usage. There are two other benzene ring regioisomers, 6-hydroxy-N,N-dimethyltryptamine (6-HO-DMT) and...

DOI: 10.1111/1556-4029.14368 (opens in new tab) Full text (opens in new tab) Psilocin Bufotenine Controlled substances Hydroxy-N,N-Dimethyltryptamine Ho-DMT +9

Psychedelics as a Treatment for Alzheimer’s Disease Dementia

Frontiers in Synaptic Neuroscience August 21, 2020 Simon Vann Jones, Allison O’kelly 60 citations

Currently, there are no disease-modifying treatments for Alzheimer's disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric...

P300‐mediated modulations in self–other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self–other overlap

Human Brain Mapping August 21, 2020 Lukasz Smigielski, Michael Kometer, Milan Scheidegger et al. 42 citations

Abstract The concept of self and self‐referential processing has a growing explanatory value in psychiatry and neuroscience, referring to the cognitive organization and perceptual differentiation of self‐stimuli in health and disease. Conditions in which selfhood loses its natural coherence offer a unique opportunity for elucidating the mechanisms underlying self‐disturbances. We assessed the...

DOI: 10.1002/hbm.25174 (opens in new tab) Psilocybin Anterior cingulate cortex Cognition Cognitive psychology +6

Case Report: Resolution of Rheumatoid Arthritis in a Patient Consuming Psilocybin Mushrooms

Journal of Healthcare August 19, 2020 S Lin Denise 2 citations

This was a retrospective database analysis of all paediatric (< 18-years) intubations performed by HEMS physicians during a six-year period (2012-2017). The recorded findings included patient demographics, operator background, airway interventions (including intubation attempts), video-assisted intubation, and complications.

DOI: 10.36959/569/456 (opens in new tab) Full text (opens in new tab) Psilocybin Demographics Rheumatoid arthritis Psychological intervention +3

Psychedelic science in post-COVID-19 psychiatry

Irish Journal of Psychological Medicine August 19, 2020 John R. Kelly, Matthew Crockett, Laith Alexander et al. 16 citations

The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising...

Delayed Anxiolytic-Like Effects of Psilocybin in Male Mice Are Supported by Acute Glucocorticoid Release

bioRxiv (Cold Spring Harbor Laboratory) August 14, 2020 N. Jones, Zarmeen Zahid, Sean M. Grady et al. 9 citations preprint

Abstract Despite observed correlations between acute glucocorticoid release, self-reported anxiety, and long-term treatment outcomes for human studies using psilocybin-assisted psychotherapy approaches, the mechanistic relationship between psychedelic-dependent stress and subsequent behavioral responses remains unclear. Using rodents, direct manipulation of stress-associated hormone responses...

The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame)

August 13, 2020 Jeffrey Guss, Robert Krause, Jordan Sloshower 86 citations preprint

The Yale Manual for Psilocybin-Assisted Therapy of Depression provides researchers and therapists with methods, structure, and areas to consider regarding the use of psychedelic- assisted therapy in the treatment of Major Depressive Disorder (MDD). In particular, this manual illustrates a mode of utilizing Acceptance and Commitment Therapy (ACT) as a therapeutic framework for...

Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms

August 5, 2020 Sofia Beck 1 citation

Depression and anxiety are debilitating mental health conditions that affect a large portion of the United States. Current pharmacological treatments for these disorders require daily administration, are associated with a number of side effects, and can be ineffective for some. Emerging evidence in novel treatment options may necessitate a shift toward how we treat these psychiatric disorders.

Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison

Schizophrenia Bulletin August 5, 2020 Pantelis Leptourgos, Martin Fortier-Davy, Robin Carhart-Harris et al. 88 citations

Abstract The recent renaissance of psychedelic science has reignited interest in the similarity of drug-induced experiences to those more commonly observed in psychiatric contexts such as the schizophrenia-spectrum. This report from a multidisciplinary working group of the International Consortium on Hallucinations Research (ICHR) addresses this issue, putting special emphasis on hallucinatory...

DOI: 10.1093/schbul/sbaa117 (opens in new tab) Full text (opens in new tab) Psilocybin Psychosis Schizophrenia spectrum Multidisciplinary approach +12

Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.

Psychopharmacology August 1, 2020 Theresa M. Carbonaro, Matthew W Johnson, Roland R. Griffiths 51 citations

Although both psilocybin and dextromethorphan (DXM) produce psychedelic-like subjective effects, rates of non-medical use of psilocybin are consistently greater than DXM. New data are presented from a study of psilocybin and DXM relevant to understanding the features of psilocybin subjective effects that may account for its higher rates of non-medical use. Single, acute oral doses of psilocybin...

Modulatory effects of ayahuasca on personality structure in a traditional framework

Psychopharmacology July 23, 2020 Nige Netzband, Simon Ruffell, Sabriya Linton et al. 56 citations

Abstract Abstract Ayahuasca is a psychoactive plant brew containing dimethyltryptamine (DMT) and monoamine oxidase inhibitors (MAOIs). It originates from the Amazon basin, where it is used primarily for ceremonial purposes. Ayahuasca tourists are now entering certain communities seeking alternative physical or psychological healing, as well as spiritual growth. Rationale Recent evidence has...

Immunochemical monitoring of psilocybin and psilocin to identify hallucinogenic mushrooms

Journal of Pharmaceutical and Biomedical Analysis July 21, 2020 Izumi Morita, Hiroyuki Oyama, Yuki Kiguchi et al. 17 citations

Development of rapid and reliable immunochemical methods for monitoring psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine; Pyb) and psilocin (dephosphorylated metabolite; Psi), the psychoactive compounds contained within hallucinogenic mushrooms (magic mushrooms), is desirable in order to identify these mushrooms and regulate their illicit use. Because no antibody was publicly available for...

DOI: 10.1016/j.jpba.2020.113485 (opens in new tab) Psilocybin Hallucinogen Monoclonal antibody Metabolite +3

21 Psychedelic treatment of functional neurological disorder – a systematic review

Journal of Neurology, Neurosurgery, and Psychiatry July 20, 2020 Matthew Butler, Mathieu Seynaeve, Timothy R. Nicholson et al.

Aims Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the most commonly encountered conditions in neurology clinics and neuropsychiatry services, yet the therapeutic evidence base is limited. Research into psychedelics such as psilocybin and lysergic acid diethylamide (LSD) is currently being...

4 Psychedelics: therapeutic mechanisms

Journal of Neurology, Neurosurgery, and Psychiatry July 20, 2020 Robin Carhart-Harris

Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University. At Imperial, he has designed and/or carried out brain imaging studies involving LSD, psilocybin, MDMA and DMT, plus a clinical trial of psilocybin for treatment-resistant depression, and an ongoing study...

DOI: 10.1136/jnnp-2020-bnpa.4 (opens in new tab) Psilocybin Hallucinogen Psychoanalysis Psychotherapist

Perceived harm, motivations for use and subjective experiences of recreational psychedelic ‘magic’ mushroom use

Journal of Psychopharmacology July 17, 2020 Carl A Roberts, Isaac Osborne-Miller, Jon C. Cole et al. 33 citations

Background: Data on actual harm of magic mushrooms suggest that toxicity and abuse potential is low, however, their legal status suggests otherwise. We aimed to gauge perception of harm of magic mushrooms in both users and mushroom-naïve participants. We also aimed to observe differences in expectations of effects between users and mushroom-naïve participants, and whether motivations for use...

American Trip

The MIT Press eBooks July 14, 2020 Ido Hartogsohn 34 citations

How historical, social, and cultural forces shaped the psychedelic experience in midcentury America, from CIA LSD experiments the Harvard Psilocybin Project. Are psychedelics invaluable therapeutic medicines, or dangerously unpredictable drugs that precipitate psychosis? Tools for spiritual communion or cognitive enhancers that spark innovation? Activators for one's private muse or part of a...

DOI: 10.7551/mitpress/11888.001.0001 (opens in new tab) Psilocybin Counterculture Context archaeology Mindset +7